MedTrace Logo

A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis

NCT00593177 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2008-08-19

No results posted yet for this study

Summary

The primary objective of the study is to assess the tolerability and efficacy of a 0.10% or 0.05% PTH (1-34) parathyroid hormone peptide gel in the treatment of mild to moderate plaque psoriasis in comparison to treatment with the placebo gel alone.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

PTH (1-34) Gel / Placebo Gel

Topical dosing of gel twice daily for eight weeks.

Sponsors & Collaborators

  • Therapeutics, Inc.

    collaborator INDUSTRY

  • Manhattan Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Tatjana Lukic, M.D., M.Sc. · Manhattan Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-06-30
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00593177 on ClinicalTrials.gov